BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Cassava Sciences, Inc. (NASDAQ:SAVA) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/sava.
What is this all about?
The lawsuit alleges that Cassava Sciences overstated the efficacy of its Alzheimer's disease treatment candidate simufilam and failed to maintain effective data management and controls related to its drug research programs.
Who is eligible?
Anyone who purchased Cassava Sciences, Inc. stock between August ...